Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, Pillay D, Kasirye R, Mugyenyi P, Walker AS, Dunn DT; DART Trial Team. Kityo C, et al. Among authors: goodall rl. PLoS One. 2014 Mar 13;9(3):e90772. doi: 10.1371/journal.pone.0090772. eCollection 2014. PLoS One. 2014. PMID: 24625508 Free PMC article. Clinical Trial.
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.
INITIO Trial International Co-ordinating Committee; Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, Floridia M, Girard PM, Goodall RL, Hooker MH, Mijch A, Meiffredy V, Salzberger B. INITIO Trial International Co-ordinating Committee, et al. Among authors: goodall rl. Lancet. 2006 Jul 22;368(9532):287-98. doi: 10.1016/S0140-6736(06)69074-0. Lancet. 2006. PMID: 16860698 Clinical Trial.
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Kaleebu P, Pillay D; Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Ndembi N, et al. Among authors: goodall rl. J Infect Dis. 2010 Jan 1;201(1):106-13. doi: 10.1086/648590. J Infect Dis. 2010. PMID: 19938977 Clinical Trial.
52 results